Biological characterization of genetic variants identified in genome-wide association studies (GWAS) remains a substantial challenge. Here we used human-induced pluripotent stem cells (iPSC) and their neural derivatives to characterize common variants on chromosome 3p22 that have been associated by GWAS with major mental illnesses. IPSC-derived neural progenitor cells carrying the risk allele of the single nucleotide polymorphism (SNP), rs9834970, displayed lower baseline TRANK1 expression that was rescued by chronic treatment with therapeutic dosages of valproic acid (VPA). VPA had the greatest effects on TRANK1 expression in iPSC, NPC, and astrocytes. Although rs9834970 has no known function, we demonstrated that a nearby SNP, rs906482, strongly affects binding by the transcription factor, CTCF, and that the highaffinity allele usually occurs on haplotypes carrying the rs9834970 risk allele. Decreased expression of TRANK1 perturbed expression of many genes involved in neural development and differentiation. These findings have important implications for the pathophysiology of major mental illnesses and the development of novel therapeutics.
Introduction
Genome-wide association studies (GWASs) of bipolar disorder (BD) and schizophrenia (Scz) have identified several reproducible genetic markers, but the biological consequences of most variants remain undefined [1, 2] . Many common complex traits are mediated by expression quantitative trait loci (eQTLs) that affect expression of nearby (cis) or distant (trans) genes [3] . Altered gene expression is thus an important mechanism underlying genotype-phenotype associations [4] . However, eQTLs may act only in specific tissues [5] [6] [7] or particular stages of development [8, 9] . Such tissue and time-specific effects complicate studies of allelic variation and gene expression in the human central nervous system (CNS), where appropriate cells from living individuals are difficult to obtain. Past eQTL studies of variants implicated in brain disorders have thus depended on limited supplies of post mortem brain tissue [10] . Such studies are valuable, but cannot directly assess developmental effects and are often confounded by age, gender, medications, substance abuse, and agonal events.
Induced pluripotent stem cells (iPSC) offer an attractive alternative [11] . eQTL studies in human iPSC-derived cells exploit a renewable supply of cells largely free from the complications of post mortem tissue. iPSC can be easily generated from patients of known genetic background, further reducing variance that can obscure subtle signals. Model systems based on iPSC-derived cells can follow changes in gene expression during development and can be experimentally manipulated with drugs, toxins, or geneediting. While iPSC-derived cells can be affected by culture conditions [12] or somatic changes in DNA sequence or copy number [13, 14] and do not reflect all epigenetic marks in the donor's brain [4] , they nevertheless offer great potential for dissecting the molecular mechanisms of complex brain disorders. Several recent studies have employed iPSC technology to model neuropsychiatric conditions in vitro [15] [16] [17] [18] , but few such studies have investigated common risk variants [19] .
In this study, we used iPSC and their neural derivatives to investigate the cellular impact of common genetic polymorphisms previously associated with BD and Scz by GWAS. The polymorphisms lie on chromosome 3p22 near the gene TRANK1 (also known as LBA1). TRANK1 encodes a protein of unknown function expressed in brain and other tissues. A common variant (rs9834970) located some 15 kb 3′ of TRANK1 has shown genome-wide significant association with BD in several GWAS [20] [21] [22] ; nearby markers have been associated with Scz and other mental illnesses [23, 24] . We previously showed that valproic acid (VPA), an effective treatment for BD, increases TRANK1 expression in immortalized cells [20] , but the relationship between VPA exposure, genetic risk variants, and expression of TRANK1 in non-immortalized neural cells remains unclear.
The present study had several objectives: (1) to assess the impact of common variants within the 3p22 locus on TRANK1 expression in patient-derived neural cells; (2) to test the effects of treatment with VPA and another commonly used therapeutic agent, lithium, on TRANK1 expression; and (3) to uncover genes and gene networks whose expression correlates with that of TRANK1, thereby shedding light on its function.
Results

Induction and characterization of iPSCs and neural derivatives
All lines exhibited typical stem-cell morphology. Immunofluorescence demonstrated expression of pluripotency markers (Fig. 1a) . Flow cytometry was consistent with pluripotency ( Fig. 1b) . We found good consistency of differentiation between samples: more than 96% of putative NPC were Nestin-positive; after 8 week of neuronal differentiation, >80% of cells stained positive for MAP2, and >80% of these were also positive for vesicular glutamate transporter (vGLUT2), consistent with glutamatergic neurons. Some cells stained positive for tyrosine hydroxylase (TH), consistent with dopaminergic neurons. After 7 week of astrocyte differentiation, >80% of cells stained positive for GFAP and A2B5. Representative images are shown in Fig. 1a . Differentiated neurons displayed action potentials by patch-clamp (Fig. 1c) . These neurons also stained positive for postsynaptic density 95 (PSD95) (Fig. 1d) .
Gene expression profiles demonstrated distinct clusters for fibroblasts, iPSCs, NPCs, and neurons, as expected ( Figure S1a ). All studied iPSC lines exhibited gene expression profiles typical of pluripotent stem cells (Figure S1b, c) . qRT-PCR of selected pluripotency and NPC markers further validated these cell lines ( Figure S2a, b) . All iPSC lines maintained normal karyotypes ( Figure S2c ; Supplemental Methods).
TRANK1 expression after VPA treatment in iPSCs and neuronal derivatives Previously, we showed that VPA increased expression of TRANK1 in immortalized, non-neural cell lines [20] . To assess the effects of VPA on neural cells, monolayercultured iPSCs, and neural derivatives were treated with VPA. In iPSCs and NPCs, TRANK1 expression increased threefold to sixfold after 72 h treatment with VPA (Fig. 2a) . Expression increased with VPA dosage over the typical therapeutic range of 0.5 to 1.0 mM. VPA also significantly increased TRANK1 expression in astrocytes, but less than in iPSC or NPCs. In contrast, VPA had no detectable effect on TRANK1 expression in neurons. A similar lack of change in TRANK1 expression was seen in rat hippocampal neurons treated for up to 5 days with VPA doses as high as 2 mM (Fig. 2b) . These results show that VPA has the greatest effects on TRANK1 expression in actively growing cells, diminishing with differentiation.
VPA also reversed the effects of stable shTRANK1 knockdown in HeLa cells (n = 6) (Fig. 2c ). This suggests that VPA affects TRANK1 expression at the level of transcription.
Unlike VPA, but consistent with our published results in immortalized cells [20] , lithium chloride had no effect on TRANK1 expression in any of the iPSC-derived cells we tested (Fig. 2d) . Thus, subsequent experiments focused on VPA.
Genetic variation at rs9834970 and TRANK1 expression in iPSCs and neural derivatives Previous GWAS have found that the G-allele of rs9834970 is significantly more frequent than the A-allele among people with BD or schizophrenia [2, [20] [21] [22] [23] [24] [25] [26] . This SNP lies about 15 kb downstream of TRANK1, within a DNase I hypersensitive site (ENCODE). Conditional analysis of BD GWAS data confirmed that rs9834970 fully accounted for the association signal at this locus ( Figure S3 ). To test whether variation at rs9834970 affects expression of TRANK1, we compared TRANK1 expression in iPSCs, NPCs, and neurons.
Genotype at rs9834870 had a substantial impact on baseline expression of TRANK1 mRNA in both iPSC and NPC. Cell lines carrying the risk allele (AG or GG genotypes) showed significantly lower baseline TRANK1 expression than AA homozygotes. NPCs with the GG genotype (n = 3) showed a 5.6-fold decrease in TRANK1 expression (p < 0.0001) compared to the AA genotype (n = 3) and a 1.35-fold decrease (p < 0.05) compared to the AG genotype (n = 5) (Fig. 2e) . Similar results were seen in iPSCs, where GG homozygotes showed significantly lower baseline TRANK1 expression than AA homozygotes (p < 0.0001; Figure S4 ).
To test whether similar genotype effects could be detected in post mortem brain, we used RNA-sequencing data obtained from human dorsolateral prefrontal cortex [27] . Baseline expression of TRANK1 was very low, and no genotype-specific effects were observed (Fig. 2h) . SNP rs9834970 also showed no evidence of association with TRANK1 expression in any of the 10 brain regions in BRAINEAC [28] (Figure S5 ) or in any of the tissues reported by GTEX (http://www.gtexportal.org, accessed 1/ 12/2018). These results suggest that rs9834970 does not affect expression of TRANK1 in mature brain or exerts celltype-specific effects not easily detected in bulk tissue.
VPA treatment rescues expression of TRANK1 in riskallele carriers
Chronic treatment with therapeutic doses of VPA increased expression of TRANK1 in NPC carrying the risk allele of rs9834970, normalizing expression in those cells (Fig. 2e , middle and right panels). Both 0.5 mM and 1 mM VPA significantly increased TRANK1 expression in risk-allele carriers. ANOVA analysis confirmed a significant VPA by genotype interaction (F (1,46) = 4.45; p < 0.05), indicating that increased TRANK1 expression after VPA treatment (Fig. 1a) is driven by lines with AG or GG genotypes.
Western blotting in cell lysates derived from NPC confirmed that TRANK1 protein expression was lower in risk (G) allele carriers than in AA homozygotes, and that VPA treatment increased expression of TRANK1 protein (Fig. 2f,  g ). We conclude that VPA treatment rescued expression of TRANK1 mRNA and protein in NPCs carrying the risk allele at rs9834970. No significant effect of genotype or VPA on TRANK1 expression was detected in neurons (data not shown).
Predicted regulatory effects of rs9834970 and nearby SNPs
Several common SNPs are in strong linkage disequilibrium with rs9834970 (Fig. 3a) . Five of these SNPs have been associated with BD and/or schizophrenia in previous GWAS [20, [22] [23] [24] 29] . In European-ancestry populations, SNPs in this region form four common haplotypes, two of which carry the rs9834970 risk allele (Fig. 3b , yellow highlight). Both haplotypes also carry the "G" allele at rs906482 (Fig. 3b , white boxed region).
Functional annotation by the Roadmap Epigenomics and ENCODE projects [30] indicates many SNPs in this region have an impact on chromatin state or transcription factor binding in various tissues (Fig. 3c ), but only rs906482 alters DNA-protein binding. This SNP alters binding by the zinc finger protein, CTCF, in multiple cell types (http://insula tordb.uthsc.edu). Since CTCF is an important gene regulatory protein in vertebrates [31] , we further investigated the impact of rs906482 on CTCF binding in NPCs. Electrophoretic mobility shift assays (EMSA) were performed using probes surrounding rs906482. CTCF peptide displayed significantly higher affinity for the (G) allele at rs906482 ( Fig. 3d-f ). As noted above, this allele usually resides on the same haplotype as the risk (G) allele of rs9834970 (Fig. 3b) . These results suggest that common genetic variation near TRANK1 affects expression through a CTCF-mediated mechanism.
In light of these results, we repeated the eQTL analyses with rs906482 genotype as the independent variable. The results were similar to those observed for rs9834970, with an even stronger baseline relationship between genotype and TRANK1 expression. As with rs9834970, VPA also rescued TRANK1 expression in carriers of the G-allele at rs906842 ( Figure S6 ).
Genome-wide gene expression profiles
To explore the impact of decreased TRANK1 expression at the cellular level, two stable knockdowns of TRANK1 were generated with TRANK1 shRNA lentiviral constructs in HeLa cells. The extent of TRANK1 knockdown assessed at both mRNA and protein levels was substantial (Fig. 4a, b) . Fig. 2 Effects of cell type, drug treatment, and rs9834970 genotype on TRANK1 expression. a Human-induced pluripotent stem cell (iPSC), neural progenitor cell (NPC), neuronal, and astrocyte lines were grown in independent cultures and treated with therapeutic dosages of VPA (0.5 mM, 1 mM) or vehicle for 72 h. TRANK1 mRNA expression was determined by reverse transcription polymerase chain reaction (RT-PCR). VPA treatment significantly increased TRANK1 expression in iPSCs, NPCs, and astrocytes, but not in neurons (*P < 0.05, **P < 0.01). b TRANK1 expression in rat E18 hippocampal neurons cultured for 8 days before treatment was also unaffected by VPA, even after 48 h or 5 days of treatment at 2 mM dose. c TRANK1 expression in HeLa cells was significantly increased by treatment with 1 mM or 2 mM VPA after stable shRNA knockdown of TRANK1. **P < 0.01 TRANK1 shRNA knockdown vs no-target shRNA control. ## P < 0.01 VPA (1 mM or 2 mM) treated vs untreated condition.^^P < 0.01 shRNA TRANK1_66 knockdown vs no-target control shRNA on 2 mM VPA treatment condition. d Lithium (1 mM) had no effect on TRANK1 expression in any of the four cell types tested. e Neural progenitor cells (NPCs) carrying the risk allele (G) showed reduced TRANK1 mRNA expression (left) that was rescued by 72 h of VPA treatment at dosages of 0.5 mM (middle) or 1 mM (right). Values are expressed as mean relative ΔCT difference ± S.E.M. Comparisons: baseline, GG vs AA, p < 0.0001; baseline, GG vs AG, p < 0.05; baseline, GG vs VPA 0.5 mM, GG, p < 0.05; baseline GG vs VPA 1 mM, GG, p < 0.01. n = 3 for GG carries; n = 3 for AA carries; n = 5 for AG carries. f Western blot: Qualitative increase in binding of anti-TRANK1 antibody to 274 kDa protein band extracted from NPCs in A-allele carriers vs G-allele carriers at both untreated and after treatment with 1 mM VPA conditions; n = 3 for each condition. g Quantification of western blot signal intensities with imageJ, **P < 0.01 VPA treated vs untreated, rs9311137  rs931913  rs4678553  rs9311138  rs7646422  rs7646626  rs4678554  rs9834970  rs906482  rs1027840  rs1006834  rs1507882  rs4624519  rs9917659   rs4789  rs12637912  rs3796186  rs9811916  rs4234258 .324
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.105 Genome-wide gene expression profiling of knockdown lines revealed many differentially expressed genes. The 214 genes differentially expressed with an absolute fold change > 1.75 at an FDR < 0.05 (Table S1) were enriched for increased cell proliferation and survival and decreased apoptosis (Table 1a) . Gene set enrichment analysis (GSEA) indicated that these genes were strongly enriched for the Gene Ontology (GO) terms "regulation of cell proliferation," "multicellular organismal development," and "system development" (Table S2) .
To further examine the effect of TRANK1 knockdown, we assessed cellular proliferation quantitatively using the MTT assay (Supplementary Methods). As expected, cellular proliferation was significantly increased in the knockdown lines at 2-3 days, compared with the no-target scrambled controls (p < 0.001, Figure S8 ). , and e HDAC2, in iPSC (n = 4), NPC (n = 11), neurons (n = 5), and astrocytes (n = 2). **p < 0.01, all cell types compared to iPSCs; ## p < 0.01, neurons, and astrocytes compared to NPCs. f Increase in TRANK1 mRNA expression during 14 weeks of neuronal differentiation and maturation. **p < 0.01, compared to 7-week neurons. g Relative HDAC1 and TRANK1 expression in TRANK1 knockdown HeLa cells (n = 6). **p < 0.01, compared to notarget control shRNA. Four gene-specific shRNA sequences designed for human TRANK1 gene; one negative construct and one "non-target" construct were transduced separately into HeLa cells (Table S7) . HeLa cells were seeded in 48-well plates (50% confluent) overnight, and infected with lentivirus at multiplicity of infection (MOL) of 10, with serum-free, antibiotic-free DMEM media containing 8 μg/ml of Polybrene (Sigma-Aldrich, St. Louis, MO). After 6 h, the lentiviral shRNA medium was removed and replaced with DMEM-containing 20% FBS. Forty-eight hours post transfection, the cells were seeded into a 6-well plate and propagated in complete DMEM medium with 20% FBS and 3 µg/ml puromycin until colonies were visible. The puromycin-resistant clones were picked and expanded, and the knockdown efficiency was verified by quantitative RT-PCR and western blot. The two constructs with the best knockdown efficiency (over 70%), along with non-target shRNA control, were used for gene expression array studies Since VPA treatment increased TRANK1 expression, we expected that VPA treatment of iPSC-derived NPCs would produce a gene expression profile that contrasted with that seen in the TRANK1 knockdown. The 304 genes differentially expressed in VPA-treated NPCs (absolute fold change > 1.75, FDR < 0.05) were analyzed (Table S3 ). As expected, these genes were enriched for decreased proliferation of cells and decreased growth of axons (Table 1B) . Similarly, GSEA revealed significant enrichment for GO terms "cell differentiation," "nervous system development," "neurogenesis," and "neuron differentiation" (Table S4) .
Consistent with these results, treatment of NPCs with VPA substantially decreased cell proliferation in vitro ( Figure S8 ) Increasing TRANK1 expression with differentiation and inverse relationship with expression of histone deacetylases Among the genes whose expression was increased most by TRANK1 knockdown (Table S1 ) was histone deacetylase 1 (HDAC1), which is known to be inhibited by VPA [32] . To more fully characterize the relationship between TRANK1 and HDAC1, we compared relative HDAC1 and TRANK1 expression in iPSCs, NPCs, neurons, and astrocytes. TRANK1 expression was highest in neurons (Fig. 4c) , while HDAC1 expression was highest in iPSCs and NPCs (Fig. 4d, e) . TRANK1 expression rose steadily during neuronal maturation (Fig. 4f) , while knockdown of TRANK1 in HeLa cells led to a substantial increase in HDAC1 expression (Fig. 4g) . These data suggest a reciprocal relationship between TRANK1 and HDAC1 expression in developing cells.
Discussion
This study used human iPSCs and neural derivatives to investigate the impact of common genetic variation and drug treatment on gene expression at a locus implicated by GWAS of major mental illnesses. The results demonstrated a link between common SNPs at the locus and expression of the nearby gene, TRANK1, in neural cells. The results also showed, for the first time, that the mood stabilizer, VPA, rescues TRANK1 expression in neural cells carrying risk alleles at this locus. Although rs9834970 has no known function, an associated nearby SNP, rs906482, strongly affects binding by the transcription factor, CTCF. Decreased expression of TRANK1 perturbed many genes involved in neural development, differentiation, and apoptosis.
This study has some limitations. The number of iPSCderived cell lines was limited, reducing power to detect subtle effects. Additional signals may emerge as sample size increases. Both rs9834970 and rs906482 reside upon a haplotype that carries many common variants related to chromatin regulation and transcription factor binding (Figure S9) ; additional SNPs may contribute to the biological impact of the risk haplotype. GWAS have also identified other SNPs associated with BD and schizophrenia in this region [2, 21, 24, 33] , some of which are not in strong linkage disequilibrium with rs9834970. Further studies that use genome editing techniques such as CRISPR/Cas9 would be needed to establish the functional impact of each SNP. Variants within the locus may affect additional genes not investigated in the present study. Some of the genomewide expression data was based on shTRANK1 knockdown in HeLa cell lines, which are very different from NPCs. Drugs can be an important influence on gene expression. This study focused on VPA since it is an effective treatment for BD and demonstrated robust effects on TRANK1 expression in previous studies [20] . However, the other drug we studied, lithium, had no apparent impact on TRANK1 expression. The TRANK1 region has also been associated with schizophrenia, and VPA is not known to exert a therapeutic effect in that mental illness. Further studies will be needed to explore the full range of drugs affecting expression of TRANK1 in neural cells.
These results suggest that therapeutic effects of VPA in BD may be due in part to expression of TRANK1. VPA normalized TRANK1 expression in cells carrying the risk haplotype. Moreover, TRANK1 regulated many of the same cellular growth and differentiation pathways that are known to be affected by VPA, highlighting a key role for histone deacetylases, known targets of VPA. VPA affected TRANK1 expression mainly in growing cells, consistent with the observation that exposure to VPA is teratogenic during early nervous system development [33, 34] . The failure of neurons to display increased TRANK1 expression after VPA treatment may reflect high baseline expression of TRANK1 in neurons. However, the number of neuron lines was limited and we noted considerable variation in baseline TRANK1 expression across lines, so it is possible that subtle effects were missed. It is not obvious from these data how VPA would exert a beneficial effect in the mature brain. VPA did have a significant impact on TRANK1 expression in astrocytes, suggesting one way that the therapeutic window could extend into adulthood. Recent work has highlighted the potential importance of astrocytes and other glia in the pathophysiology of neuropsychiatric disorders [35] [36] [37] . It is also possible that VPA acts on developing neurons originating during adult neurogenesis.
This study demonstrated reciprocal effects of TRANK1 and HDAC1 on gene expression, cell proliferation, and differentiation. We observed an increase in TRANK1 expression over baseline in more differentiated cells, where HDAC1 expression was decreased. Proof of a causal relationship between TRANK1 and HDAC1 expression would require experimental over-expression of TRANK1, beyond the scope of this study. These data are consistent with a model whereby HDAC1 inhibition by VPA normalizes TRANK1 expression in carriers of the risk allele. However, VPA affects many genes by inhibiting histone deacetylases, so the effect of VPA is not specific to expression of TRANK1. Future studies are needed to assess whether other HDAC inhibitors have similar effects. In any case, the results are consistent with a role for VPA and other histone deacetylase inhibitors in neuronal growth and differentiation [34, 38, 39] .
While the precise mechanism whereby VPA and genetic variation near TRANK1 affect gene expression remains to be fully elucidated, our findings suggest an important role for CTCF. We showed that genetic variation within risk haplotypes alters CTCF binding, and that decreased binding correlates with increased expressed of TRANK1. Recent CHIP-seq data from the ENCODE Project also shows substantial CTCF binding in the vicinity of rs906482. CTCF influences gene expression by acting as a transcriptional insulator, orchestrating longrange DNA-looping interactions between distal enhancers and their cognate promoters [40] . Genome-wide analysis of CTCF has demonstrated its crucial role in higher-order chromatin organization that can increase or curtail enhancer-promoter interactions, depending on the relative positions of these regulatory elements [25] . Increased CTCF binding to the risk allele may block the effect of a distal enhancer that otherwise activates TRANK1 expression. Finding that enhancer is an important future goal that may suggest other approaches to regulation of TRANK1 expression in brain.
We speculate that CTCF may also have a role in the mechanism whereby VPA impacts TRANK1 expression. CTCF can recruit histone deacetylases to the transcription activation complex [41] . VPA also decreases CTCF expression [42] . VPA may thus antagonize gene repression by CTCF.
This study illustrates a strategy to investigate GWAS findings in neuropsychiatric disorders. Genotype-specific iPSC-derived cells can be used to study allelic variation and gene expression across a range of cell types, developmental stages, and environmental conditions, offering a degree of cellular, temporal, and experimental resolution not possible with blood or post mortem brain. We report what appears to be a cell-type-specific effect of a cisregulatory variant on gene expression, consistent with recent findings that cis-regulation can differ between brain regions [43] , developmental stages [44] , and cell types [45] . iPSCs and neural derivatives also provide a platform for screening therapeutic drugs in patientspecific cells. We have shown how such studies can identify potentially causal genetic variants, enhance understanding of disease mechanisms, and illuminate relationships between genetic variation and treatments for neuropsychiatric disorders.
Methods
See Supplementary Methods for details.
Reprogramming
All 11 iPSC lines used in this study (Table S5) were generated from the fibroblasts using lentiviral transduction with STEMCCA vector (Millipore) [46] . Pluripotency was assessed by immunostaining for pluripotency markers, flow cytometry quantification, qPCR for specific markers, and PluriTest [47] . iPSCderived cells were characterized by standard immunochemical analysis, qRT-PCR, and electrophysiology. iPSC clones that displayed a normal karyotype were selected for further studies (Fig. S2c) .
Generation of NPCs and differentiation into neurons and astrocytes
iPSC lines were differentiated into NPCs using AggreWell TM 800 plates (StemCell Technologies) in STEMdiff TM neural induction medium. Neuronal differentiation was induced by Neurobasal (Invitrogen), supplemented with 1 × B27 (Invitrogen), 10 ng/ml BDNF (Peprotech), 10 ng/ml GDNF (Peprotech), L-ascorbate (200 ng/ml), and cAMP (1 µM) (Sigma-Aldrich). Cells were cultured in neuron medium for > 2 mo. For astrocyte differentiation, NPCs were plated on Geltrex-coated culture dishes in STEMdiff TM Neural Progenitor Medium. After 2 days, medium was changed to DMEM, 1% N2 supplement (Invitrogen), and 1% FBS, 20 ng/ml CTNF (R&D Systems). Hippocampal neurons were prepared from fetal rat brain at embryonic day 18 as described [48] .
Genotyping and quantitative real-time PCR (qPCR)
Expression of selected genes was determined using Roche LightCycler 480 and Universal ProbeLibrary System. The C T method was used to quantify relative mRNA levels. Primer sequences are presented in Table S6 .
Samples were genotyped on the Illumina Infinium Human OmniExpress Exome bead array. To further validate genotypes in NPCs and detect rare variants, 400 bp flanking rs9834970 was Sanger-sequenced at Macrogen ( Figure S10 ).
Western blotting
Protein isolation was performed with M-PER lysis buffer (ThermoScientific, Catalog 78503). Concentration was determined using a spectrophotometer. Overall, 25 μg protein was loaded onto 4-12% Tris-Glycine gels, electrophoresed, and transferred with iBlot 2 onto nitrocellulose membranes (Life Technologies). Membranes were blocked, incubated with anti-TRANK1 antibody washed 5× with TBST, and incubated with secondary antibody. After washing, membranes were exposed to Amersham TM ECL TM Western blotting detection reagents (GE Healthcare) and quantified with ImageJ.
RNA interference
MISSION™ shRNA Lentiviral Transduction Particles (Sigma-Aldrich) were used for the knockdown study. Four gene-specific shRNA sequences designed for human TRANK1, one negative construct and one "non-target" construct were transduced separately into HeLa cells (Table S7 ). The two constructs with >70% knockdown efficiency, along with a scrambled no-target shRNA control, were used for expression studies.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed with the Gel shift chemiluminescent kit (Active Motif). Table S8 lists sequences for synthetic double-stranded consensus CTCF and 5′ biotin-labeled oligonucleotides corresponding to rs906482. sequence of consensus CTCF double-stranded oligonucleotide was derived from a site previously described to bind to CTCF. CTCF-associated peptide was affinity purified as described [49, 50] . Oligonucleotide probes were designed with both alleles of rs906482, flanked by14 bp, in both a cold and 5′-biotinylated form (IDT). For each binding reaction, 5-10 pmol purified CTCF peptide was incubated for 20 min at room temperature with 20 fmol biotin-labeled duplex oligonucleotide containing the A or G-allele, with or without consensus CTCF oligonucleotide in binding buffer. Supershift was generated by anti-CTCF antibody. After incubation, the mixture was loaded on a 6% DNA retardation gel (EC6365BOX, Life Technologies), separated by electrophoresis, and transferred to a nylon membrane that was UV cross-linked and detected by chemiluminescence using stabilized streptavidin-horseradish peroxidase conjugate (Pierce). For competition assays, unlabeled consensus oligonucleotides at 100-fold molar excess were added before the biotin-labeled probe. bands were quantified using ImageJ.
Microarray analysis
Gene expression profiling was performed on RNA extracted from: (a) NPC lines treated for 72 h with 0.5 mM VPA or vehicle; (b) HeLa lines with stable knockdown by TRANK1 shRNA particles; and (c) one HeLa line with notarget shRNA control (n = 8 for each condition). Groups were equally divided between array plates and hybridization batches. Total RNA, extracted with the RNeasy Mini kit (QIAGEN, Hilden, Germany) was used for cDNA amplification, Cy3 labeling, and hybridization onto Illumina HT-12_V4 beadchips. Microarray data were assembled using GenomeStudio V3.0 (Illumina). Raw expression data were log2 transformed and quantile normalized using a custom R script calling Bioconductor (www.bioconductor. org). Outliers were checked by inter-sample correlations and principal component analysis. Transcripts were considered robustly expressed and included in the analysis if the coefficient of variation lay within the linear phase of the distribution. Differential expression was tested by one-way ANOVA. Gene set enrichment analysis was carried out with DAVID [51, 52] , at medium stringency, with background comprising all robustly expressed probes differentially expressed genes were also analyzed with GeneSpring.
